Loading…
← CockpitCompetitor Analysis › 4147.TWO TaiMed Biologics Inc.Open in the cockpit ↗

TaiMed Biologics Inc.4147.TWOCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Biotechnology
Momentum leader 84
Mkt cap
$480M
US dollars, full cap
Free float
77%
of shares outstanding
$/day
$1.71M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-11.3 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
120 days
18 Mar 2027
Close · TWDNT$60.60
1D-4.9%
1W-2.1%
1M-0.8%
3M-5.6%
6M+18.6%
YTD-1.0%
1Y-13.9%
ATR %4.6%
52w lowhigh19.6% off high

What TaiMed Biologics does

No business profile yet.

TaiMed Biologics at a glance

Size TaiMed Biologics (4147.TWO) is a Taiwan Health Care company (Biotechnology) with a market value of $480M, the 446th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$60.60 on 18 Nov 2026.

Performance Over six months the shares gained 18.6%, against -14.1% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 4th highest of 18 in its peer set.

Growth Revenue grew 7.0% over the last twelve months (peer median -9.2%); the operating margin is -31.0% (peer median -11.6%).

Valuation It trades at 22.7× enterprise value to sales against a peer median of 7.5× (4th most expensive of 14).

Capital Return on invested capital runs 11.3 points below its cost of capital (5.0% WACC).

Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 20264147.TWO 121Peer median 84
Six months, rebased to 100: TaiMed Biologics against the median of its 20 peers (local-currency closes).

TaiMed Biologics financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$650MNT$611MNT$610MNT$492MNT$563M
Revenue growth—0%+24%-13%—
Gross profitNT$252MNT$203MNT$155MNT$168MNT$154M
EBITDA-NT$47.0M-NT$41.7M-NT$98.6M-NT$11.5M-NT$36.0M
Net income-NT$164M-NT$168M-NT$202M-NT$195M-NT$269M
Free cash flow-NT$48.7MNT$168M-NT$388M-NT$31.8M-NT$609M
Capital expenditureNT$57.4MNT$22.8MNT$19.4MNT$6.15MNT$4.76M
Total debtNT$471MNT$493MNT$523MNT$751MNT$766M

Quarterly statements and history in the cockpit →

TaiMed Biologics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%+20%MNPRNGNECBIO6586603255FENC688247KMDADMAC300858STTKVLA04196011518065894147.TWO6-month return →1-month return →
Up and to the right = strong over both horizons. TaiMed Biologics is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×2,500×5,000×7,500×6586603255FENC688247KMDA300858VLA11518065894147.TWORevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. TaiMed Biologics is the large dot.

TaiMed Biologics competitors and peer comparison

How TaiMed Biologics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

TaiMed Biologics against its 20 peers (data as of 18 Nov 2026)
Measure4147.TWOPeer medianRank in peer set
1-month return-0.8%-11.1%4th highest of 21
6-month return+18.6%-14.1%4th highest of 18
Distance from 52-week high-19.6%-46.1%3rd highest of 21
Revenue growth (TTM)+7.0%-9.2%4th highest of 15
Operating margin-31.0%-11.6%7th lowest of 15
EV / Sales22.7×7.5×4th most expensive of 14
ROIC minus cost of capital-11.3 pp-5.7 pp5th lowest of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
TaiMed Biologics 4147.TWOTaiwan$480M+19%+7%-31%22.7×n/an/a
Monopar Therapeutics MNPRUnited States$479M+9%n/an/an/an/an/a
Neurogene NGNEUnited States$479M-14%-100%n/an/an/an/a
Crescent Biopharma CBIOUnited States$482M-34%n/a-1,217%13.3×n/an/a
CHO Pharma 6586.TWOTaiwan$488M+24%-47%-17,694%8,281.1×n/an/a
Liaoning Dingjide Petrochemical 603255.SSChina$490M-24%+70%5%5.2×n/an/a
Fennec Pharmaceuticals FENCUnited States$471M+37%+71%5%6.4×58.8%+204.7%
TenNor Therapeutics Suzhou 6872.HKHong Kong$470Mn/an/an/an/an/an/a
Sinotherapeutics 688247.SSChina$494M-19%-17%0%6.2×29.4%+7.0%
Kamada KMDAUnited States$465M+3%+5%15%2.0×5.0%+6.5%
DiaMedica Therapeutics DMACUnited States$463M+50%n/an/an/an/an/a
HanchorBio 7827.TWTaiwan$462Mn/an/a-4,673%509.6×n/an/a
Beijing Scitop Bio-Tech 300858.SZChina$501M-28%+4%8%7.5×n/an/a
Shattuck Labs STTKUnited States$455M-28%-100%n/an/an/an/a
Valneva VLA.PAFrance$508M-6%-27%-87%3.9×n/an/a
Komipharm International 041960.KSSouth Korea$454M-2%-6%-1%11.8×n/an/a
LongBio Pharma (Suzhou) 1779.HKHong Kong$510Mn/an/an/an/an/an/a
Qurient 115180.KSSouth Korea$452M-56%-14%-512%84.4×n/an/a
Beijing Bohui Innovation Biotechnology 300318.SZChina$518M-20%-1%-13%6.2×n/an/a
EirGenix 6589.TWTaiwan$444M+15%+58%-51%9.9×n/an/a
Arvinas ARVNUnited States$443M-26%-12%-10%n/an/an/a

Questions

Which companies are TaiMed Biologics's closest peers?
The cockpit's peer set: Monopar Therapeutics (MNPR), Neurogene (NGNE), Crescent Biopharma (CBIO), CHO Pharma (6586.TWO), Liaoning Dingjide Petrochemical (603255.SS), Fennec Pharmaceuticals (FENC), TenNor Therapeutics Suzhou (6872.HK), Sinotherapeutics (688247.SS).
Is TaiMed Biologics expensive compared with its peers?
On ev / sales it trades at 22.7× against a peer median of 7.5×, 4th most expensive of 14 in its peer set.
How has TaiMed Biologics stock performed?
Over six months to 18 Nov 2026 the shares returned +18.6% against -14.1% for the median peer; over one year -13.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.